Manufacturers continue to grapple with quality control issues. Traditional inspection methods are failing to meet the demands of modern production, with high-profile contamination incidents like stainless steel particles in Moderna vaccines exposing critical vulnerabilities.¹ Manual inspection remains prone to human error, whilst conventional automated systems can only detect what they’ve been programmed to find. As regulatory scrutiny intensifies and production complexity increases, manufacturers need a solution.
AI automated technology represents a sophisticated evolution in visual inspection that addresses fundamental limitations of both manual and traditional automated approaches. Promising to transform pharmaceutical quality assurance, artificial intelligence-driven inspection offers the capability to achieve zero-defect production whilst maintaining commercial viability.
The Regulatory Imperative
Regulatory bodies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA), are progressively expecting manufacturers to demonstrate robust quality control capabilities that extend beyond traditional compliance measures. Current Good Manufacturing Practice (cGMP) incorporates strict contamination control protocols designed to prevent foreign particles from compromising pharmaceutical products, with enforcement becoming increasingly stringent across global markets.
The FDA’s Guidance for Industry on the Inspection of Injectable Products for Visible Particulates requires that all medicinal products intended for parenteral administration be visually inspected for particulate matter, and that any container showing visible particulates must be rejected.² In addition, the United States Pharmacopoeia guidance on visible particulates in injections establishes regulatory requirements for visual inspection of parenteral products, enforcing demonstration through 100% visual inspection that batches are “essentially free of visible particulates” before release.³ These regulations underscore the critical importance of comprehensive inspection capabilities in pharmaceutical manufacturing.
Currently, no AI-specific regulations are in place, though the EU has drafted GMP Annex 22 (Artificial Intelligence) and Annex 11 (Computerised systems), which are under review. A key regulatory principle emerging from these drafts is that for critical GMP applications, only static or deterministic models are permitted, whilst dynamic or continually learning models are not acceptable for critical GMP uses.⁴ ⁵ This regulatory framework means AI models must be locked and static when deployed in inspection machines for production, with self-learning capabilities reserved for development and future releases rather than automatic onsite production model updates.
Given that AI-specific regulations remain in draft stages, AI-based inspection machines are currently governed by the same regulatory framework as traditional inspection machines. The EU policy on automated visual inspection (AVI) states: “where automated methods of inspection are used, the process should be validated to detect known defects (which may impact product quality or safety) and be equal to, or better than, manual inspection methods”.⁶
Many AI automated inspection systems support the various compliance frameworks by creating comprehensive audit trails that satisfy regulatory documentation requirements, providing manufacturers with defensible quality assurance processes.
